SCHEMBL6401593

SCHEMBL6401593

COc1ccc2c(c1)COC2(C(F)(F)F)C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 2/20 0.42
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
KDM1A O60341 1/20 0.38
ALDH1A1 P00352 1/20 0.37
DRD2 P14416 2/20 0.37
DRD3 P35462 2/20 0.37
DRD1 P21728 1/20 0.37
DRD5 P21918 1/20 0.37
ABHD6 Q9BV23 1/20 0.37
METAP1 P53582 2/20 0.36
BCL2 P10415 1/20 0.36
CHRNA7 P36544 1/20 0.36
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6403193 0.83 PDK2 (0.41) PDK2ESR1ESR2KDM1AALDH1A1
SCHEMBL6401340 0.83 PDK2 (0.41) PDK2ESR1ESR2KDM1AALDH1A1
SCHEMBL6403380 0.83 PDK2 (0.41) PDK2ESR1ESR2KDM1AALDH1A1
SCHEMBL6399956 0.77 PDK2 (0.43) PDK2KDM1AALDH1A1DRD2DRD3
SCHEMBL12491421 0.77 DRD2 (0.41) KDM1AALDH1A1DRD2DRD3DRD1
SCHEMBL17591321 0.75 PDK2 (0.42) PDK2ESR1ESR2ALDH1A1DRD2
SCHEMBL6400531 0.72 PDK2 (0.43) PDK2ESR1ESR2KDM1AALDH1A1
SCHEMBL6406622 0.72 PDK2 (0.43) PDK2ESR1ESR2KDM1AALDH1A1
SCHEMBL6400509 0.72 PDK2 (0.43) PDK2ESR1ESR2KDM1AALDH1A1
SCHEMBL8108541 0.71 PDK2 (0.36) PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171354-A1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists PFIZER INC. (US) 2005-08-04 US claimed
US-20030208079-A1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists PFIZER INC. 2003-11-06 US claimed
EP-1032571-B1 PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS PFIZER (US) 2002-06-12 EP claimed
US-20050171354-A1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists PFIZER INC. (US) 2005-08-04 US disclosed
US-20030208079-A1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists PFIZER INC. 2003-11-06 US disclosed
EP-1032571-B1 PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS PFIZER (US) 2002-06-12 EP disclosed
EP-1032571-A1 PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 2000-09-06 EP disclosed
WO-1999025714-A1 PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 1999-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171354-A1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists HRH2, TACR1, HRH4 PDK2 3515/4885ESR1 497/4885ESR2 674/4885
US-20030208079-A1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists TACR1, HRH2, GRPR PDK2 4168/4885ESR1 989/4885ESR2 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.